Marty St. Clair

TL;DR: Dysregulated immune activation was partially corrected by this regimen; however, the perturbed expression of T cell receptor V regions in the CD4 and CD8 T lymphocyte populations was not significantly affected.

TL;DR: CSF HIV RNA may be a surrogate marker for brain infection, based on the observed correlation with brain levels, and the association between plasma HIV RNA and CSF levels of HIV and β2‐microglobulin suggests that both viral load and CNS immune activation are important determinants of neurological disease.

TL;DR: Both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral comparator group and the primary analysis used a Bayesian approach to evaluate the hypothesis that the proportion with viral suppression for each long- acting regimen is not worse than the oral regimen proportion.

TL;DR: Immune restoration was incomplete in patients who started HAART with moderately advanced HIV-1 disease and most changes occurred during the first year, suggesting that this degree of suppression of HIV- 1 replication alone will not suffice to restore immune competence.

TL;DR: Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravIR-abacavir-lamivudine with regard to maintaining HIV-1 suppression.